|
FIGO stage (stage I–II vs. stage III–IV)
|
2.244 (0.922–5.462)
|
0.075
|
1.092 (0.257–4.639)
|
0.905
|
|
Histologic grade (G1–2 vs. G3–4)
|
1.313 (0.833–2.07)
|
0.24
| | |
|
Primary therapy outcome (SD-PD vs. PR-CR)
|
0.299 (0.201–0.443)
|
< 0.001
|
0.296 (0.169–0.517)
|
< 0.001
|
|
Age (< 60 vs. ≥ 60)
|
1.248 (0.944–1.65)
|
0.12
| | |
|
Tumor residual (NRD vs. RD)
|
2.559 (1.572–4.166)
|
< 0.001
|
2.991 (1.526–5.86)
|
0.001
|
|
Lymphatic invasion (no vs. yes)
|
1.407 (0.816–2.425)
|
0.219
| | |
|
Venous invasion (no vs. yes)
|
0.846 (0.45–1.591)
|
0.604
| | |
|
Anatomic subdivision (unilateral vs. bilateral)
|
1.034 (0.747–1.431)
|
0.841
| | |
|
TP53 mutation (no vs. yes)
|
0.643 (0.386–1.07)
|
0.089
|
1.026 (0.565–1.861)
|
0.934
|
|
BRCA mutation (no vs. yes)
|
0.596 (0.313–1.134)
|
0.115
| | |
|
ATP1A1 (low vs. high)
|
1.135 (0.857–1.501)
|
0.377
| | |
|
ATP1A2 (low vs. high)
|
1.304 (0.984–1.727)
|
0.064
|
1.413 (0.958–2.085)
|
0.082
|
|
ATP1A3 (low vs. high)
|
1.572 (1.188–2.081)
|
0.002
|
1.723 (1.169–2.54)
|
0.006
|
|
ATP1A4 (low vs. high)
|
0.721 (0.544–0.956)
|
0.023
|
0.611 (0.408–0.916)
|
0.017
|
